National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent Neoplasms

High Priority Recommendations • Conduct large-scale, long-term (>10 years), systematic follow-up of HCT recipients to better define the magnitude of risks for specific SN types, including both common and rarer tumors. The full spectrum of SN should be considered, including certain benign tumors (...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2016-09, Vol.23 (3), p.367-378
Main Authors: Morton, Lindsay M., PhD, Saber, Wael, MD, MS, Baker, K. Scott, MD, MS, Barrett, A. John, MD, Bhatia, Smita, MD, MPH, Engels, Eric A., MD, MPH, Gadalla, Shahinaz M., MD, PhD, Kleiner, David E., MD, PhD, Pavletic, Steven, MD, Burns, Linda J., MD
Format: Article
Language:English
Subjects:
Hematology, Oncology and Palliative Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High Priority Recommendations • Conduct large-scale, long-term (>10 years), systematic follow-up of HCT recipients to better define the magnitude of risks for specific SN types, including both common and rarer tumors. The full spectrum of SN should be considered, including certain benign tumors (e.g., meningioma) as well as all types of cutaneous malignancies. • Collect detailed patient and clinical data (e.g., primary disease, pre- and post-transplant therapies, donor source, GVHD type/severity/therapy, adherence to screening recommendations, exposure to key cancer risk factors such as tobacco) in a standardized format to investigate determinants of SN risks. • Bank cryopreserved donor and recipient blood and marrow cells and SN tissues to enable interdisciplinary clinical and laboratory investigations of SN susceptibility and pathogenesis.
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2016.09.005